The prevalence of chronic airflow obstruction in three cities in the Nordic-Baltic region.

To access publisher's full text version of this article click on the hyperlink below Chronic airflow obstruction (CAO) is the primary characteristic of Chronic obstructive pulmonary disease (COPD) but is also seen in chronic asthma. To compare the prevalence of CAO and possible risk factors bet...

Full description

Bibliographic Details
Published in:Respiratory Medicine
Main Authors: Broström, Erika, Jõgi, Rain, Gislason, Thorarinn, Benediktsdottir, Bryndis, Burney, Peter G J, Janson, Christer
Other Authors: 1 Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Sweden. 2 Lung Clinic, Tartu University Hospital, Tartu, Estonia. 3 Department of Sleep, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Iceland. 4 Faculty of Medicine, University of Iceland, Iceland. 5 National Heart and Lung Institute, Imperial College, London, UK. 6 Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Sweden; National Heart and Lung Institute, Imperial College, London, UK. Electronic address: christer.janson@medsci.uu.se.
Format: Article in Journal/Newspaper
Language:English
Published: W.B. Saunders 2018
Subjects:
Asthma
COPD
Chronic airflow obstruction
Gender difference
Smoking
Öndunarfærasjúkdómar
Langvinn lungnateppa
Lungnasjúkdómar
Pulmonary Disease
Chronic Obstructive
Iceland
Online Access:http://hdl.handle.net/2336/620730
https://doi.org/10.1016/j.rmed.2018.08.007
Description
Summary:To access publisher's full text version of this article click on the hyperlink below Chronic airflow obstruction (CAO) is the primary characteristic of Chronic obstructive pulmonary disease (COPD) but is also seen in chronic asthma. To compare the prevalence of CAO and possible risk factors between Tartu in Estonia, Reykjavik in Iceland and Uppsala in Sweden. All participants underwent spirometry testing of forced expiratory volume in 1 s (FEV 1037 men and 956 women participated in the study. The prevalence of CAO was lower in women in Tartu compared to the other centres (4.9% vs. 13.4 and 8.7% in Reykjavik and Uppsala, respectively, p = 0.002) while no difference was found for men. A similar picture was seen for the proportion of participants that had smoked 10 pack years or more which was much lower in Tartu for women than in Reykjavik and Uppsala, respectively (13.2% vs. 33.7 and 29.2%, p < 0.001). (Fig. 1). Of the participants with CAO the majority (57-67%) did not have a previous diagnosis of asthma or COPD. ALTANA Aventis AstraZeneca Boehringer-Ingelheim Chiesi GlaxoSmithKline Merck Novartis Pfizer Schering-Plough Sepracor University of Kentucky Landspitali-University Science Fund Astra Zeneca in Iceland GlaxoSmithKline in Iceland Swedish Heart-Lung Foundation Swedish Heart and Lung Association GlaxoSmithKline, Sweden Astra Zeneca

Similar Items